SP100

Across TCGA pan-cancer cohorts, SP100 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SP100 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SP100 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SP100 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where SP100 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.226	0.507	<.001	40	view →
HNSC	DFS	Tertile	All	0.978	0.305	.008	21	view →
LUAD	DFS	Median	All	0.960	0.871	.015	10	view →
GBM	DFS	Tertile	All	0.634	0.840	.007	9	view →
LSCC	DFS	Tertile	II,III,IV	0.472	0.827	.015	8	view →
CCRCC	DFS	Median	All	0.888	0.978	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SP100–PDAC (OS)

Open the PDAC breakdown →